SCHEMBL6854526

SCHEMBL6854526

Oc1cncc(Cl)n1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bicarbonate SCHEMBL8778741 0.91 CDK2 (0.43)
SCHEMBL138054 0.78
SCHEMBL9779717 0.78
SCHEMBL30172433 0.72
SCHEMBL376275 0.72
SCHEMBL14797510 0.67 CDK2 (0.44)
SCHEMBL29526991 0.67
SCHEMBL27858703 0.67 GRM5 (0.49)
SCHEMBL8447800 0.67
SCHEMBL67803 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119009136-A Pyrazinyl eutectic electrolyte with wide electrochemical stability window, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-11-22 CN claimed
EP-4695238-A1 CDK2 INHIBITORS Blueprint Medicines Corporation (US) 2026-02-18 EP disclosed
EP-4551570-A1 NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Dong-A ST Co., Ltd. (KR) 2025-05-14 EP disclosed
EP-4058445-B1 GLP-1 RECEPTOR AGONIST AND USE THEREOF ILDONG PHARMACEUTICAL CO LTD (KR) 2025-03-26 EP disclosed
US-12240836-B2 Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof DONG-A ST CO., LTD. (KR) 2025-03-04 US disclosed
CN-119403798-A Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof 东亚ST 株式会社 2025-02-07 CN disclosed
CN-119009136-A Pyrazinyl eutectic electrolyte with wide electrochemical stability window, and preparation method and application thereof 中国科学院长春应用化学研究所 2024-11-22 CN disclosed
WO-2024216154-A1 CDK2 INHIBITORS BLUEPRINT MEDICINES CORPORATION (US) 2024-10-17 WO disclosed
US-11932618-B2 GLP-1 receptor agonist and use thereof ILDONG PHARMACEUTICAL CO., LTD. (KR) 2024-03-19 US disclosed
US-20240025884-A1 COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF DONG-A ST CO., LTD. (KR) 2024-01-25 US disclosed
EP-2151439-A1 NITROGENATED AROMATIC 6-MEMBERED RING DERIVATIVE, AND PHARMACEUTICAL AGENT COMPRISING THE SAME Asubio Pharma Co., Ltd. (JP) 2010-02-10 EP disclosed
US-7160877-B2 Aliphatic nitrogen-containing 5-membered ring compound TANABE SEIYAKU CO., LTD. (JP) 2007-01-09 US disclosed
US-6831175-B2 Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine ABBOTT LABORATORIES 2004-12-14 US disclosed
EP-1463505-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER Abbott Laboratories (US) 2004-10-06 EP disclosed
EP-1412384-A2 STABLE FORMULATION OF MODIFIED GLP-1 Novo Nordisk A/S (DK) 2004-04-28 EP disclosed
US-20030199511-A1 Kinase inhibitors ABBVIE INC. 2003-10-23 US disclosed
US-20030187026-A1 Kinase inhibitors ABBOTT LABORATORIES 2003-10-02 US disclosed
WO-2003051366-A2 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER ABBOTT LABORATORIES (US) 2003-06-26 WO disclosed
WO-2003002136-A2 STABLE FORMULATION OF MODIFIED GLP-1 NOVO NORDISK A/S (DK) 2003-01-09 WO disclosed
US-5143824-A No side absorption in blue and green regions, improved color reproduction FUJI PHOTO FILM CO., LTD. (JP) 1992-09-01 US disclosed